BLA 125514 · Merck Sharp Dohme
Keytruda
Pembrolizumab · Intravenous · Programmed Death Receptor-1 Blocking Antibody
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Sep 4, 2014
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
2,769
366 Phase 3, 688 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Pembrolizumab" as an intervention, any sponsor and status, largest first.
- Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsPivotal-lookingRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT05055908 · 12,000 participants (planned) · Start Oct 1, 2021 · Primary completion Jul 1, 2025
Drug: Pemetrexed plus Pembrolizumab; Pembrolizumab and 1 more · For: Lung Cancer
Sites: Changsha, China
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03486873 · 3,500 participants (planned) · Start Aug 21, 2018 · Primary completion Aug 4, 2043
Drug: Pembrolizumab; Standard of Care (SOC) and 5 more · For: Solid Tumors; Hematologic Malignancies
Sites: Tucson, Arizona; Bakersfield, California; Fresno, California · 782 sites in all
- Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent SystemNot yet recruiting
NING LIAcademic, hospital or other
NCT06824792 · 3,000 participants (planned) · Start Mar 1, 2025 · Primary completion Feb 29, 2028
Drug: Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE. · For: Advanced Solid Tumors
Sites: Langfang, China
- Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast CancerPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT06606730 · 2,454 participants (planned) · Start Jul 23, 2025 · Primary completion Jan 1, 2033
Drug: Pembrolizumab · For: Breast Cancers; Triple Negative Breast Cancer (TNBC)
Sites: Brussels, Belgium; Villejuif, France
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT05929768 · 2,400 participants (planned) · Start Sep 15, 2023 · Primary completion Mar 31, 2033
Drug: Carboplatin; Cyclophosphamide and 4 more · For: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8 and 2 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 963 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Keytruda (Pembrolizumab)
2024 spending
$140M
Beneficiaries
1,906
11,882 claims
Per beneficiary
$73,481
$1,390.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $57,022,095 |
| 2021 | $68,680,806 |
| 2022 | $91,147,955 |
| 2023 | $116,820,430 |
| 2024 | $140,055,040 |
Part B: Keytruda (Pembrolizumab) · HCPCS J9271
2024 spending
$5.99B
Beneficiaries
75,361
455,858 claims
Per beneficiary
$79,464
2024 ASP limit $56.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,501,098,225 |
| 2021 | $3,966,530,837 |
| 2022 | $4,935,971,049 |
| 2023 | $5,433,584,763 |
| 2024 | $5,988,521,233 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
Janjigian YY, Kawazoe A, Bai Y, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, et al. · Lancet 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.
Uppaluri R, Haddad RI, Tao Y, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
Pusztai L, Denkert C, O'Shaughnessy J, et al. · Ann Oncol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
Tolaney SM, de Azambuja E, Kalinsky K, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.